



Legacy Healthcare to Present RAAINBOW Phase 2/3 Clinical Trial Data at European Society for Pediatric Dermatology Congress

Epalinges, Switzerland, 15 April 2024 - - Legacy Healthcare, a Swiss-based biotechnology company developing first-in-class botanical drugs for human health, today announced that it will present phase 2/3 data from its RAAINBOW trial at the 23rd annual congress of the European Society for Pediatric Dermatology taking place in Kosice, Slovakia, from 2-4 May, 2024.

“Alopecia areata remains a vastly unserved market, particularly for pediatric patients for which there is significant room for innovation,” commented Saad Harti, Chairman & CEO of Legacy Healthcare. “Data from our RAAINBOW study with CINAINU, our first botanical drug, show significant promise and we are dedicated to advancing this and submitting for approval from regulatory authorities around the world to advance patient care.”

Data from the RAAINBOW study was presented by Professor Ulrike Blume Peytavi, MD, Deputy head of Department of Dermatology, Venerology and Allergology at Charité University, Berlin. The European Society for Pediatric Dermatology (ESPD) is a respected, independent, and non-profit organization dedicated to advancing the field of pediatric dermatology. It serves as a professional hub for dermatologists, pediatricians, and specialists in related disciplines, fostering collaboration and knowledge sharing across these fields. The ESPD is committed to promoting high standards of care and innovative research to improve the understanding and treatment of skin conditions in children. Open to professionals globally, the society plays a vital role in uniting experts to address the unique dermatological needs of pediatric patients.

For more information on the conference, please visit: <https://www.espd.info/espd2024>

About Phase 2/3 RAAINBOW trial

This randomized, placebo-controlled, double-blind study investigated Coacillium in patients from 2 to 18 years of age with alopecia areata. Patients included had moderate alopecia areata (SALT 25-50) and severe alopecia areata (SALT 50-95), and were experiencing a current episode of alopecia areata that had lasted between six months and three years (n=62). Patients were randomized to receive topical Coacillium or placebo (2:1). A treatment period of 6 months was followed by a treatment-free period of 6 months, to evaluate possible disease recurrence in successfully treated patients. The primary endpoint was the relative change in scalp alopecia areata severity score (SALT) from baseline value to be assessed after 24 weeks of treatment, evaluated through global standardised scalp photographs. A key secondary endpoint was the proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. SALT is the standard tool for measurement of the amount of scalp hair loss in alopecia areata.

For more information about the RAAINBOW trial please visit: <https://clinicaltrials.gov/ct2/show/NCT03240627>



About Legacy Healthcare

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions. The company's first product candidate, CINAINU, has demonstrated strong safety and efficacy in a phase 2/3 study involving patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children.

For more information about Legacy Healthcare please visit www.legacyhealthcare.ch

Inquiries: contact@legacyhealthcare.ch;